Oramed Pharmaceuticals Files 8-K Report

TL;DR

ORAM filed an 8-K, looks like standard reporting, no major news.

AI Summary

On September 30, 2025, Oramed Pharmaceuticals Inc. filed an 8-K report detailing other events. The company, incorporated in Delaware with its principal executive offices in New York, NY, is involved in the pharmaceutical preparations industry. This filing does not appear to contain specific financial transactions or material events beyond its routine reporting.

Why It Matters

This 8-K filing indicates a routine update from Oramed Pharmaceuticals Inc., providing transparency to investors about the company's ongoing compliance and reporting status.

Risk Assessment

Risk Level: low — The filing appears to be a routine 8-K report without disclosure of significant new risks or material events.

Key Players & Entities

• ORAMED PHARMACEUTICALS INC. (company) — Registrant
• September 30, 2025 (date) — Date of earliest event reported
• New York, New York (location) — Address of Principal Executive Offices
• 1185 Avenue of the Americas (location) — Street Address

FAQ

Key Financial Figures

• $0.012 — ch registered Common Stock, par value $0.012 ORMP The Nasdaq Capital Market, Te
• $0.0001 — res of Scilex's common stock, par value $0.0001 per share (the "Scilex Common Stock") a
• $0.01 — Common Stock") at an exercise price of $0.01 per share (the "Subject Warrants") in t
• $27,000,000 — ches for an aggregate purchase price of $27,000,000 (the "Warrant Repurchase"), subject to
• $13,000,000 — ex Common Stock for a purchase price of $13,000,000, representing the first tranche of the
• $14,000,000 — rom the Company for a purchase price of $14,000,000 on or before December 31, 2025. 1 SIG

Filing Documents

• ea0260371-8k_oramed.htm (8-K) — 22KB
• 0001213900-25-096322.txt ( ) — 183KB
• ormp-20250930_lab.xml (EX-101.LAB) — 33KB
• ormp-20250930_pre.xml (EX-101.PRE) — 22KB
• ormp-20250930.xsd (EX-101.SCH) — 3KB
• ea0260371-8k_oramed_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. As previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on July 23, 2025, on July 22, 2025, Oramed Pharmaceuticals Inc. (the "Company") entered into an Option Agreement for the Repurchase of Warrants (the "Option Agreement") with Scilex Holding Company ("Scilex") pursuant to which, among other things, the Company granted to Scilex an option to repurchase warrants held by the Company to purchase an aggregate of 6,500,000 shares of Scilex's common stock, par value $0.0001 per share (the "Scilex Common Stock") at an exercise price of $0.01 per share (the "Subject Warrants") in two tranches for an aggregate purchase price of $27,000,000 (the "Warrant Repurchase"), subject to the terms and conditions set forth in the Option Agreement. On September 30, 2025, Scilex repurchased Subject Warrants to purchase 3,130,000 shares of Scilex Common Stock for a purchase price of $13,000,000, representing the first tranche of the Warrant Repurchase. Pursuant and subject to the terms of the Option Agreement, Scilex continues to have the option to repurchase the remaining 3,370,000 Subject Warrants from the Company for a purchase price of $14,000,000 on or before December 31, 2025. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORAMED PHARMACEUTICALS INC. By: /s/ Nadav Kidron Name: Nadav Kidron Title: President and CEO October 6, 2025 2

View Full Filing

View this 8-K filing on SEC EDGAR